AcelRX Pharmaceuticals on track to initiate first ARX-01 Phase 3 clinical trial
On Thursday August 11, 2011, 7:49 am EDT
AcelRX CEO Richard King said, "During Q2, we made significant strides towards initiation of Phase 3 studies for ARX-01, our lead product candidate for acute post-operative pain, and towards initiation later this year of the Phase 2 study for ARX-04, our product candidate for management of acute pain, being developed under a grant from USAMRMC. We remain on track to initiate enrollment in the first ARX-01 Phase 3 study later this year, to be followed by initiation of the second Phase 3 study in early 2012. We anticipate data from these studies to be available in the first half of 2012."